When do you stop dantrolene in a patient with neuroleptic malignant syndrome?

Dantrolene is typically used to treat severe NMS, although the data supporting its use is mixed. The biggest risk with the therapy is hepatotoxicity. It is reasonable to discontinue dantrolene once the hyperthermia and severe muscle rigidity have resolved, or earlier if there is concern for liver injury. Extending treatment beyond the time it takes to achieve a favorable symptomatic response does not offer additional benefit and may expose the patient to liver injury risk.